Guilin Sanjin Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002275.SZ

Guilin Sanjin Pharmaceutical Co., Ltd. Operating Income for the year ending December 31, 2023: USD 73.00 M

Guilin Sanjin Pharmaceutical Co., Ltd. Operating Income is USD 73.00 M for the year ending December 31, 2023, a 12.75% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Guilin Sanjin Pharmaceutical Co., Ltd. Operating Income for the year ending December 31, 2022 was USD 64.74 M, a -4.11% change year over year.
Guilin Sanjin Pharmaceutical Co., Ltd. Operating Income for the year ending December 31, 2021 was USD 67.52 M, a 24.24% change year over year.
Guilin Sanjin Pharmaceutical Co., Ltd. Operating Income for the year ending December 31, 2020 was USD 54.35 M, a -19.38% change year over year.
Guilin Sanjin Pharmaceutical Co., Ltd. Operating Income for the year ending December 31, 2019 was USD 67.41 M, a -6.95% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

Shenzhen Stock Exchange: 002275.SZ

Guilin Sanjin Pharmaceutical Co., Ltd.

CEO	Mr. Xun Zou
IPO Date	July 10, 2009
Location	China
Headquarters	No.1, Gold Star(Jinxing) Road
Employees	2,615
Sector	Healthcare
Industries Pharmaceuticals Cosmetics Frozen Foods Non-Alcoholic Beverages Personal Care Pet Food Soft Drinks & Sodas Tobacco

Description

Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China. The company primarily offers Guilin watermelon frost and lozenge, and Sanjin tablets under the Chinese TCM brand; and Naomaitai capsules, etc. It also produces TCM preparations. The company was founded in 1967 and is headquartered in Guilin, China. Guilin Sanjin Pharmaceutical Co., Ltd. operates as a subsidiary of Guilin SanJin Group Co.,Ltd.

Key trends

Past 5 years